Analysis of data from the DANBIO registry of psoriatic arthritis patients treated with tumor necrosis factor inhibitor therapy shows that comorbidities were associated with higher baseline disease activity, shorter TNFi persistence, and reduced clinical response rates to TNFi.

A study from the Veterans Affairs clinics and the National Data Bank of Rheumatic Diseases shows that rheumatoid arthritis (RA) patients who were severely obese had a greater risk of progressive disability compared to overweight patients; that was not explained by their arthritis or inflammation.  (Citation source: 

Three years ago we published our first edition of RheumNow. We have something - and someone - to celebrate. Surprise, Dr. Jack Cush - this one’s for you! Everyone wonders how he does it. Vision. Drive. Determination. Unwavering resolve. Strength of purpose. Commitment - day in, day out. Willing to take risks. Unwilling to settle. All these, yes, but also this: passion, heart and soul.In celebration, we asked a few of his colleagues to

Dr. Jack Cush reviews the news and FDA proceedings from the past week on RheumNow.com.

Should celecoxib (Celebrex) be officially declared as no riskier for the heart than other non-steroidal anti-inflammatory drugs (NSAIDs) naproxen and ibuprofen, and do those other NSAIDs interfere with aspirin for cardiovascular prevention?

The introduction of a guest or speaker should be simple, functional and respectful. In the least, it should go something like, “I have the honor of introducing our speaker, Dr. John Brown, who comes to us from Brown University, where he is the Chief of Internal Medicine. Today he’s going to lecture on “the right way to lecture”. However, no one does this. Instead most try to do more, usually with knowledge gaps, and end up delivering

The French Vasculitis Study Group has published the results of the MAINRITSAN2 trial designed to  compare individually tailored versus fixed-schedule rituximab (RTX) reinfusion for remission maintenance in patients with antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAVs). 

I tell my patient’s that I empathize with them. I understand that they do not want a rheumatologic condition, nor do they want to take our medications and are disheartened when I tell them that we have no cures. But, if we flip that proverbial coin over, my goal for their care is to improve their quality of life.In rheumatology, we have many ways to accomplish that goal for our patients; from medication management to advocacy and support groups

On Monday, April 23rd the FDA convened the Arthritis Advisory Committee (AAC) to evaluate Lilly’s resubmitted NDA for the approval of the JAK inhibitor baricitinib for use in rheumatoid arthritis (RA). The panel included 15 voting members that included 7 rheumatologists, 3 epidemiologist-statisticians, a hematologist, 2 patient representatives and 2 pharmacologists.

The monoclonal antibody epratuzumab showed promise as a B-cell depleting agent in patients with concomitant systemic lupus erythematosus (SLE) and Sjogren's syndrome, a post-hoc analysis of two phase III trials found.

FDA staff remain worried about the safety of baricitinib, an oral JAK inhibitor intended for treatment of rheumatoid arthritis, according to briefing documents prepared for an advisory committee meeting on Monday.

The PRECISION study took 11 years and 24,081 patients (90% OA; 10% RA). It showed that celecoxib had fewer gastrointestinal events, fewer renal events and less ATPC cardiac events compared to ibuprofen - with an 18% reduction in major CV events and a 32% reduction in all-cause mortaility compared to ibuprofen.

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.  A second life for Syk kinase, Vitamin D talk, VTE, regulatory hearings and the Lupus clinic edge.

I suspect that everyone in rheumatology has a special place in their hearts for lupus patients. Their disease is so cruel, and we have so little to offer them, but the young women (and some men) that I treat keep battling on. The longer I have cared for them, the more I wanted to do for them. Managing their illness alone did not seem like enough.